1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Hodgkin Lymphoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016


DelveInsight’s Report, “Hodgkin Lymphoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Hodgkin Lymphoma Report is to understand the market and pipeline status of the drugs around the Hodgkin Lymphoma to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies. The DelveInsight’s Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Hodgkin Lymphoma. While the leading brands, companies and chemicals are considered thoroughly, DelveInsight’s report also provides details on the Global API Manufacturers across the globe covering Drug Master Filings of US, Europe and API Manufacturers in Asia specifically China and India.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE:
- A snapshot of the global Market and Phase III therapeutics scenario for Hodgkin Lymphoma.
- A review of the marketed products under prescription for Hodgkin Lymphoma, regulatory information and marketing status.
- Coverage of global patent coverage and detailed commentaries on the US patent challenges.
- Graphical representation of investigational products for patent expiry and market exclusivities across the globe.
- Product profiles for marketed products for Hodgkin Lymphoma with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
- Coverage of API Manufacturers for Hodgkin Lymphoma drugs in the United States, Europe and Asian Regions with location details.
- Coverage of Regulatory filings in theUS, Europe, and Asia specifically India and China for Hodgkin Lymphoma drugs.
- Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Hodgkin Lymphoma drugs.
- Coverage of Hodgkin Lymphoma Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress.
- Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.
- Key discontinued Marketed products.
- Global Sales Figure to 2018.

Reasons to buy
- Evaluate the marketing status and exclusivity details of Hodgkin Lymphoma key products to exploit opportunities for generic drug development opportunities.
- Identify and understand important and diverse types of therapeutics under Phase III development for Hodgkin Lymphoma.
- Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Hodgkin Lymphoma.
- API intelligence over marketed drugs forHodgkin Lymphomaand gaining primary intelligence over active ingredients manufacturers across the globe.
- API intelligence over leading Phase III Pipeline drugs.
- Develop and designstrategies by identifying the API manufacturers for Phase III Pipeline products to enhance and expand business potential and scope.
- Understanding the scope of the Phase III Drugs with nil regulatory filings.
- Understanding the chemical route of synthesis of approved drugs for Hodgkin Lymphoma.
- Uncovering opportunities in the rapidly growing US market.

Table Of Contents

Hodgkin Lymphoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

Illustrative Table of contents
1. Indication Overview
2. Market Drugs Landscape
2.1 Marketed Drugs
2.2 Marketed Details of Drugs by Application Type
2.3 Marketed Details of Drugs (NDA) by Marketing Status
2.4 Marketed Details of Drugs by Patent Expiration Timeline
3. Global API Manufacturers Assessment
3.1 API Manufacturers by United States Drug Master File (US DMF) Status
3.2 API Manufacturers by US DMF Status (Drug Specific)
3.3 API Manufacturers in Europe by Country
3.4 API Manufacturers in India by State
3.5 API Manufacturers in China by Province
3.6 Marketed Details of Approved Drugs by Geography
4. Phase III Drugs Landscape
4.1 Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs
4.2 API Manufacturers by US DMF Status (Drug Specific)
5. Drugs Market Data and Forecasted Sales Figure-2018
6. Marketed Drugs for Hodgkin Lymphoma
6.1 Drug Name
6.1.1 Drug Description
6.1.2 Global Active Pharmaceutical Manufacturers for Drug
6.1.3 Approval Status of Drug
6.1.4 Patent and Exclusivity Details for Drug
6.1.5 Company Profile and Financials
7. Phase III Drugs for Hodgkin Lymphoma
7.1 Drug Name
7.1.1 Drug Description
7.1.2 United States Drug Master File (DMF)
8. Discontinued Drugs for Hodgkin Lymphoma
9. Appendix
10. Methodology
11. Consulting Services
12. Contact Us
13. Disclaimer

List of Tables

- Hodgkin Lymphoma Therapeutic Market, US, Marketed Drugs by Application Type, 2016
- Hodgkin Lymphoma Therapeutic Market, US, Marketed Drugs by Marketing Status, 2016
- Hodgkin Lymphoma Therapeutic Market, US, (Year), 2016
- Hodgkin Lymphoma Marketed Drugs, API Manufacturers by US DMF Status, 2016
- Hodgkin Lymphoma Marketed Drugs, US DMF Status Drug Specific (Number), 2016
- Hodgkin Lymphoma Drugs, API Manufacturers, Europe by Country, 2016
- Hodgkin Lymphoma Drugs, API Manufacturers, India by State, 2016
- Hodgkin Lymphoma Drugs, API Manufacturers, China by Province, 2016
- Hodgkin Lymphoma Drugs, API Manufacturers by Geography 2016
- Hodgkin Lymphoma Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2016
- Hodgkin Lymphoma Therapeutic Market, Global Sales-2018 (in million USD)
- API Manufacturers for Drug, 2016
- Phase III Drugs for Hodgkin Lymphoma, 2016
- Discontinued Drugs for Hodgkin Lymphoma, 2016

List of Figures

- Hodgkin Lymphoma Therapeutic Market, US, Marketed Drugs by Application Type (%), 2016
- Hodgkin Lymphoma Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2016
- Hodgkin Lymphoma Therapeutic Market, US, (Year), 2016
- Hodgkin Lymphoma Marketed Drugs, API Manufacturers by US DMF Status (%), 2016
- Hodgkin Lymphoma Marketed Drugs, US DMF Status Drug Specific (Number), 2016
- Hodgkin Lymphoma Drugs, API Manufacturers, Europe by Country, 2016
- Hodgkin Lymphoma Drugs, API Manufacturers, India by State, 2016
- Hodgkin Lymphoma Drugs, API Manufacturers, China by Province, 2016
- Hodgkin Lymphoma Drugs, API Manufacturers by Geography 2016
- Hodgkin Lymphoma Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2016
- Hodgkin Lymphoma Therapeutic Market, Global Sales 2018 (in million USD)
- Drug, Patent/Exclusivity Expiry (Year), 2016

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Epiomic Epidemiology Series: Hodgkin's Lymphoma Forecast in 17 Major Markets 2016-2026

Epiomic Epidemiology Series: Hodgkin's Lymphoma Forecast in 17 Major Markets 2016-2026

  • $ 5112
  • Industry report
  • October 2016
  • by Black Swan Analysis Ltd132

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Hodgkin’s Lymphoma in 17 Major Markets Hodgkin’s Lymphoma (HL) is a cancer (also known as Hodgkin Disease, Hodgkin Lymphoma o ...

Non-Hodgkin’s Lymphoma (NHL) - Market Insights, Epidemiology and Market  Forecast-2023

Non-Hodgkin’s Lymphoma (NHL) - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Non-Hodgkin’s Lymphoma (NHL) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the ...

Small lymphocytic lymphoma- Market Insights, Epidemiology and Market Forecast-2023

Small lymphocytic lymphoma- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Small lymphocytic lymphoma - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.